Search results for: Health Data and Statistics
Filter search results
Measuring Health: a Practical Approach
7 January 1988
…this is at least in part because today’s newspaper, radio and television producers, researchers, newscasters and programme people are generally young, attractive and healthy. Compared with older people, they have…
Tuberculosis
1 October 1998
The first Office of Health Economics (OHE) disease state booklet, written in 1962, was entitled ‘Progress against Tuberculosis’ and was published at a time of great optimism among health care…
Updating the Cost of a New Chemical Entity
1 February 1999
The objective of this paper is to analyse the existing estimates of NCE costs and look at the subsequent changes in cost components and at the impact of structural change…
Benchmarking and Incentives in the NHS
5 January 2000
…comparative performance, reviews the application of benchmarking in the public and private sectors, and then examines the application of benchmarking in the UK National Health Service (NHS). A key issue…
Migraine
1 September 1991
…and recognised for more than 2,000 years, migraine has rarely commanded significant professional… ‘Choose something common and you will find little is known about it’ (Henry Head to the young…
An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates
1 February 2015
…that it is feasible to generate meaningful health state values in the UAE, though some adaptation of the methods may be required to improve their acceptability among Emiratis (and other…
EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings
27 February 2025
Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on an individual’s health state…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
…of the healthcare system and political factors which can have an effect. In the pharmaceutical industry, intellectual property (IP) rights protection including patents, data exclusivity (DE), and supplementary protection certificates…
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
…evaluate the clinical and economic value of health care interventions − prescription drugs, diagnostic tests, and a range of others − and innovations in the delivery of care. ICER involves…